OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 102,623 shares of the biopharmaceutical company’s stock, valued at approximately $2,555,000.
Other large investors also recently modified their holdings of the company. Horizon Financial Services LLC lifted its holdings in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer during the 4th quarter valued at about $28,000. HFM Investment Advisors LLC lifted its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Abound Financial LLC bought a new position in shares of Pfizer in the 4th quarter worth approximately $31,000. Institutional investors own 68.36% of the company’s stock.
Trending Headlines about Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer reaffirmed its 2026 guidance and said its strategic outlook remains intact, which should help limit downside if investors focus on fundamentals rather than the management change. Pfizer stock slides following CFO exit, 2026 guidance reaffirmed
- Positive Sentiment: The company moved quickly to appoint an interim finance chief, suggesting Pfizer has a planned transition process in place rather than a broader disruption to operations. Pfizer Announces Chief Financial Officer Transition
- Neutral Sentiment: News coverage also noted that Pfizer’s recent move is part of a broader investor debate about the company’s near-term growth catalysts and pipeline execution, rather than a change to its core business outlook. Reuters coverage of CFO departure
- Negative Sentiment: The biggest overhang is the unexpected departure of the CFO, which can create uncertainty about financial discipline and near-term investor confidence, helping explain why PFE has been declining. Pfizer CFO to leave company for consumer goods role
Analysts Set New Price Targets
View Our Latest Research Report on Pfizer
Pfizer Trading Up 0.2%
Pfizer stock opened at $25.25 on Friday. The firm has a 50 day moving average of $26.22 and a 200 day moving average of $26.33. The firm has a market capitalization of $143.94 billion, a price-to-earnings ratio of 19.28 and a beta of 0.34. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.
Pfizer Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s payout ratio is 131.30%.
Pfizer Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
